Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -2.7% Market Closed
Market Cap: 190.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Net Margin
Arovella Therapeutics Ltd

-5 615.8%
Current
-5 521%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-5 615.8%
=
Net Income
-8.7m
/
Revenue
155.7k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
AU
Arovella Therapeutics Ltd
ASX:ALA
189.1m AUD
-5 616%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
744.2B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
373.9B USD
17%
US
Merck & Co Inc
NYSE:MRK
258.4B USD
19%
CH
Roche Holding AG
SIX:ROG
200.6B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
13%
CH
Novartis AG
SIX:NOVN
180.7B CHF
35%
US
Pfizer Inc
NYSE:PFE
146.9B USD
7%
Country AU
Market Cap 189.1m AUD
Net Margin
-5 616%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 744.2B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.3T DKK
Net Margin
35%
Country US
Market Cap 373.9B USD
Net Margin
17%
Country US
Market Cap 258.4B USD
Net Margin
19%
Country CH
Market Cap 200.6B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 180.7B CHF
Net Margin
35%
Country US
Market Cap 146.9B USD
Net Margin
7%
No Stocks Found

Arovella Therapeutics Ltd
Glance View

Market Cap
189.1m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
0.01 AUD
Overvaluation 96%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-5 615.8%
=
Net Income
-8.7m
/
Revenue
155.7k
What is the Net Margin of Arovella Therapeutics Ltd?

Based on Arovella Therapeutics Ltd's most recent financial statements, the company has Net Margin of -5 615.8%.